AstraZeneca Pharma India Limited received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) on August 7, 2026, to import and distribute Enhertu for an additional indication in the treatment of breast cancer. The permission allows the company to market Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion in India for this specific use case, subject to any remaining statutory approvals.

The approval expands the therapeutic application of Enhertu to include the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer. Specifically, it targets patients who have residual invasive disease following neoadjuvant treatment with Trastuzumab, with or without Pertuzumab, combined with taxane-based therapy. This development enables AstraZeneca to address a critical gap in post-neoadjuvant care for high-risk HER2-positive patients.

Regulatory Details

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 8, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The CDSCO, operating under the Directorate General of Health Services of the Government of India, granted the permission to import the drug for sale and distribution.

Clinical Indication Scope

The newly approved indication focuses on the adjuvant setting, which involves treatment given after primary surgery or other initial therapies to reduce the risk of cancer recurrence. The eligibility criteria require patients to have HER2-positive status confirmed via IHC 3+ or ISH+ testing. Furthermore, patients must exhibit residual invasive disease despite undergoing prior neoadjuvant regimens involving Trastuzumab and taxanes.

What This Means for Market Access

This regulatory milestone paves the way for AstraZeneca Pharma India to commercialize Enhertu for this specific patient segment. While the CDSCO approval is a decisive step, the company noted that marketing activities remain subject to the receipt of related statutory approvals, if any. The expansion of indications strengthens AstraZeneca’s oncology portfolio in the Indian market, offering a targeted solution for patients who do not achieve complete pathological response to standard neoadjuvant therapies.

AstraZeneca Pharma disclosed on July 30, 2026, that it has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The notice demands ₹148.66 crore, inclusive of interest, representing a significant potential financial liability stemming from pricing compliance issues dating back nearly a decade. This development follows a show cause notice issued by the regulator in September 2025, highlighting ongoing scrutiny of the company's pricing mechanisms for its respiratory drug portfolio.

The demand notice was received by the company on July 29, 2026, and relates specifically to the product Symbicort Turbuhaler 160/4.5 (Inhaler). The NPPA alleges that AstraZeneca Pharma India Limited overcharged customers for this medication during the period from May 2016 to November 2025. The total amount demanded includes principal dues plus interest calculated up to August 20, 2026. The regulator has stipulated that the payment must be made within 30 days from the receipt of the notice.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the filing submitted to both the BSE Limited and the National Stock Exchange of India Limited.

What the Numbers Show

The magnitude of the demand—₹148.66 crore—underscores the cumulative impact of alleged pricing deviations over a nine-and-a-half-year period. The inclusion of interest calculated up to August 20, 2026, suggests that the financial burden will continue to grow if the matter is not resolved promptly. For a pharmaceutical company, such regulatory penalties can affect net profit margins and cash flow projections, particularly if the liability is recognized in the current fiscal year. The specific focus on Symbicort Turbuhaler indicates that the NPPA’s scrutiny may be concentrated on high-volume respiratory treatments, which are critical to the company’s domestic revenue stream.

The company stated it is currently evaluating the demand notice and appropriate legal actions. No immediate financial provision has been disclosed in this filing, leaving investors to assess the potential impact on future earnings. The outcome of this regulatory action could set a precedent for how pricing compliance disputes are resolved in the pharmaceutical sector under DPCO, 2013.